利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.032 秒)

    Arylthiobenzylpiperidine derivatives
    11.
    发明申请
    Arylthiobenzylpiperidine derivatives 审中-公开
    芳硫基苄基哌啶衍生物

    公开(公告)号：US20060079683A1

    公开(公告)日：2006-04-13

    申请号：US10961432

    申请日：2004-10-08

    申请人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

    发明人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

    IPC分类号： C07D413/14 ,  C07D401/14

    CPC分类号： C07D211/60 ,  C07D211/26 ,  C07D401/04 ,  C07D401/12 ,  C07D401/14

    摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject an amount of a compound of the subject invention.

    摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括给予受试者一定量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括给予受试者一定量的本发明化合物。

    Arylthiobenzylpiperidine derivatives
    12.
    发明申请
    Arylthiobenzylpiperidine derivatives 失效
    芳硫基苄基哌啶衍生物

    公开(公告)号：US20060079523A1

    公开(公告)日：2006-04-13

    申请号：US11231601

    申请日：2005-09-21

    申请人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

    发明人： Mohammad Marzabadi ,  Yu Jiang ,  Chien-An Chen ,  Kai Lu ,  Kim Andersen

    IPC分类号： A61K31/5377 ,  A61K31/496 ,  A61K31/4545 ,  C07D413/14 ,  C07D403/14 ,  C07D401/14

    CPC分类号： C07D401/04 ,  C07D211/26 ,  C07D211/62 ,  C07D401/12 ,  C07D401/14

    摘要： This invention is directed to Arylthiobenzylpiperidine derivatives which are ligands at the MCH1 receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a pharmaceutical composition made by admixing a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention. This invention also provides a method of treating a subject suffering from obesity which comprises administering to the subject a therapeutically effective amount of a compound of the subject invention.

    摘要翻译： 本发明涉及作为MCH1受体的配体的芳硫基苄基哌啶衍生物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明还提供通过混合治疗有效量的本发明化合物和药学上可接受的载体制备的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了治疗患有抑郁症和/或焦虑症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。 本发明还提供了治疗患有肥胖症的受试者的方法，其包括向受试者施用治疗有效量的本发明化合物。

    Selective NPY (Y5) antagonists
    13.
    发明申请
    Selective NPY (Y5) antagonists 审中-公开
    选择性NPY（Y5）拮抗剂

    公开(公告)号：US20080045524A1

    公开(公告)日：2008-02-21

    申请号：US11716925

    申请日：2007-03-12

    申请人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Mahesh Desai

    发明人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Mahesh Desai

    IPC分类号： A61K31/53 ,  A61K31/426 ,  A61K31/5377 ,  C07D251/54 ,  C07D413/12 ,  C07D417/04 ,  C07D413/14 ,  C07D277/38 ,  A61P3/00 ,  A61K31/4436

    CPC分类号： C07D401/12 ,  C07D251/70 ,  C07D277/28 ,  C07D277/42 ,  C07D403/12 ,  C07D409/12 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D513/04

    摘要： This invention is directed to triazine derivatives, bicyclic compounds and tricyclic compounds which are selective antagonists for a NPY (Y5) receptor. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. This invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. The invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

    摘要翻译： 本发明涉及作为NPY（Y5）受体的选择性拮抗剂的三嗪衍生物，双环化合物和三环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。 本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了本发明化合物在制备用于治疗异常的药物组合物中的用途，其中通过降低人Y5受体的活性来减轻异常。

    Selective NPY (Y5) antagonists
    15.
    发明申请
    Selective NPY (Y5) antagonists 失效
    选择性NPY（Y5）拮抗剂

    公开(公告)号：US20050137240A1

    公开(公告)日：2005-06-23

    申请号：US11040328

    申请日：2005-01-20

    申请人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Peter Buhlmayer ,  Heinrich Rueger ,  Yasuchika Yamaguchi ,  Walter Schilling

    发明人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Peter Buhlmayer ,  Heinrich Rueger ,  Yasuchika Yamaguchi ,  Walter Schilling

    IPC分类号： C07D277/42 ,  C07D277/60 ,  C07D417/12 ,  C07D513/04 ,  A61K31/426 ,  C07D277/38

    CPC分类号： C07D277/60 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04

    摘要： This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

    摘要翻译： 本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环和三环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。 本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了本发明化合物用于制备用于治疗异常的药物组合物的用途，其中所述异常通过降低人Y5受体的活性而减轻。